These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 7712130)

  • 1. Benzodiazepine peptidomimetic inhibitors of farnesyltransferase.
    Marsters JC; McDowell RS; Reynolds ME; Oare DA; Somers TC; Stanley MS; Rawson TE; Struble ME; Burdick DJ; Chan KS
    Bioorg Med Chem; 1994 Sep; 2(9):949-57. PubMed ID: 7712130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and structural requirements of potent peptidomimetic inhibitors of p21ras farnesyltransferase.
    Qian Y; Blaskovich MA; Saleem M; Seong CM; Wathen SP; Hamilton AD; Sebti SM
    J Biol Chem; 1994 Apr; 269(17):12410-3. PubMed ID: 8175645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro.
    James GL; Goldstein JL; Brown MS
    J Biol Chem; 1995 Mar; 270(11):6221-6. PubMed ID: 7890759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A non-peptide mimetic of Ras-CAAX: selective inhibition of farnesyltransferase and Ras processing.
    Vogt A; Qian Y; Blaskovich MA; Fossum RD; Hamilton AD; Sebti SM
    J Biol Chem; 1995 Jan; 270(2):660-4. PubMed ID: 7822292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time-dependent inhibition of protein farnesyltransferase by a benzodiazepine peptide mimetic.
    Roskoski R; Ritchie PA
    Biochemistry; 2001 Aug; 40(31):9329-35. PubMed ID: 11478901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent inhibition of human tumor p21ras farnesyltransferase by A1A2-lacking p21ras CA1A2X peptidomimetics.
    Nigam M; Seong CM; Qian Y; Hamilton AD; Sebti SM
    J Biol Chem; 1993 Oct; 268(28):20695-8. PubMed ID: 8407887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance of K-RasBV12 proteins to farnesyltransferase inhibitors in Rat1 cells.
    James G; Goldstein JL; Brown MS
    Proc Natl Acad Sci U S A; 1996 Apr; 93(9):4454-8. PubMed ID: 8633088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pseudopeptide inhibitors of Ras farnesyl-protein transferase.
    Graham SL; deSolms SJ; Giuliani EA; Kohl NE; Mosser SD; Oliff AI; Pompliano DL; Rands E; Breslin MJ; Deana AA
    J Med Chem; 1994 Mar; 37(6):725-32. PubMed ID: 8145221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells.
    James GL; Goldstein JL; Brown MS; Rawson TE; Somers TC; McDowell RS; Crowley CW; Lucas BK; Levinson AD; Marsters JC
    Science; 1993 Jun; 260(5116):1937-42. PubMed ID: 8316834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonfarnesylated tetrapeptide inhibitors of protein farnesyltransferase.
    Goldstein JL; Brown MS; Stradley SJ; Reiss Y; Gierasch LM
    J Biol Chem; 1991 Aug; 266(24):15575-8. PubMed ID: 1874715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tetrapeptide inhibitors of protein farnesyltransferase: amino-terminal substitution in phenylalanine-containing tetrapeptides restores farnesylation.
    Brown MS; Goldstein JL; Paris KJ; Burnier JP; Marsters JC
    Proc Natl Acad Sci U S A; 1992 Sep; 89(17):8313-6. PubMed ID: 1518863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitors of farnesyltransferase and Ras processing peptidase.
    Hall CC; Watkins JD; Ferguson SB; Foley LH; Georgopapadakou NH
    Biochem Biophys Res Commun; 1995 Dec; 217(3):728-32. PubMed ID: 8554591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequence requirement for peptide recognition by rat brain p21ras protein farnesyltransferase.
    Reiss Y; Stradley SJ; Gierasch LM; Brown MS; Goldstein JL
    Proc Natl Acad Sci U S A; 1991 Feb; 88(3):732-6. PubMed ID: 1992464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Farnesyltransferase inhibitors: a new class of cancer chemotherapeutics.
    Koblan KS; Kohl NE; Omer CA; Anthony NJ; Conner MW; deSolms SJ; Williams TM; Graham SL; Hartman GD; Oliff A; Gibbs JB
    Biochem Soc Trans; 1996 Aug; 24(3):688-92. PubMed ID: 8878827
    [No Abstract]   [Full Text] [Related]  

  • 15. Potent, cell active, non-thiol tetrapeptide inhibitors of farnesyltransferase.
    Hunt JT; Lee VG; Leftheris K; Seizinger B; Carboni J; Mabus J; Ricca C; Yan N; Manne V
    J Med Chem; 1996 Jan; 39(2):353-8. PubMed ID: 8558502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and synthesis of non-peptide Ras CAAX mimetics as potent farnesyltransferase inhibitors.
    Qian Y; Vogt A; Sebti SM; Hamilton AD
    J Med Chem; 1996 Jan; 39(1):217-23. PubMed ID: 8568811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Probing the hydrophobic pocket of farnesyltransferase: aromatic substitution of CAAX peptidomimetics leads to highly potent inhibitors.
    Qian Y; Marugan JJ; Fossum RD; Vogt A; Sebti SM; Hamilton AD
    Bioorg Med Chem; 1999 Dec; 7(12):3011-24. PubMed ID: 10658608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel conformationally extended naphthalene-based inhibitors of farnesyltransferase.
    Burns CJ; Guitton JD; Baudoin B; Lelièvre Y; Duchesne M; Parker F; Fromage N; Commerçon A
    J Med Chem; 1997 Jun; 40(12):1763-7. PubMed ID: 9191950
    [No Abstract]   [Full Text] [Related]  

  • 19. The Ras farnesylation inhibitor BZA-5B increases the resistance to cisplatin in a human melanoma cell line.
    Fokstuen T; Rabo YB; Zhou JN; Karlson J; Platz A; Shoshan MC; Hansson J; Linder S
    Anticancer Res; 1997; 17(4A):2347-52. PubMed ID: 9252645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different amino acid replacements in CAAX-tetrapeptide based peptidomimetic farnesyltransferase inhibitors.
    Schlitzer M; Sattler I; Dahse HM
    Arch Pharm (Weinheim); 1999 Apr; 332(4):124-32. PubMed ID: 10327885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.